Oncology · Medical Literature
[Articles] Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, double-blind, placebo-controlled, phase 3 trial
Abstract
In previously-treated patients with locally advanced or metastatic, radioactive iodine-refractory BRAFV600E-positive differentiated thyroid cancer, dabrafenib plus trametinib showed significant benefits for progression-free survival and overall response rate, with no new safety signals. These findings support the second-line use of dabrafenib plus trametinib in patients with radioactive iodine-refractory BRAFV600E-positive differentiated thyroid cancer.
Clinical relevance
In previously treated adults with locally advanced or metastatic, radioactive iodine-refractory, BRAF V600E-positive differentiated thyroid cancer, does the combination of dabrafenib plus trametinib improve progression-free survival and overall response rate compared with placebo? __SNAPSHOT__ {"studyDesign":"Randomized, double-blind, placebo-controlled, phase 3 trial","setting":"42 sites in 11 countries (global, multi-national); enrollment December 2021 – May 2024","sampleSize":"n=153 (dabrafenib + trametinib: ~102 [2:1 allocation], placebo: ~51 [2:1 allocation])","population":"Adults aged ≥18 years with locally advanced or metastatic, radioactive iodine-refractory, BRAF V600E-positive differentiated thyroid cancer; ECOG performance status 0–2; disease progression after one or two prior VEGFR-targeted therapies","intervention":"Dabrafenib 150 mg orally twice daily plus trametinib 2 mg orally once daily","comparator":"Matching double-blind placebo (2:1 randomization); stratified by number of prior VEGFR-targeted therapies and prior lenvatinib use","primaryOutcome":"Progression-free survival (PFS), assessed by blinded independent review committee using RECIST v1.1","followUp":"Median follow-up 17.4 months","fundingSource":"Industry (Novartis Pharmaceuticals)"}
Key findings
PRIMARY OUTCOME — PFS: Dabrafenib plus trametinib significantly extended median PFS to 12.8 months versus 3.7 months with placebo (HR=0.38; p<0.0001), representing a 62% relative reduction in the risk of progression or death. The PFS benefit was broadly consistent across predefined subgroups. SECONDARY OUTCOMES — ORR: The overall response rate (ORR) was 57% with the combination versus 4% with placebo (p<0.0001), including complete responses in 6% vs. 2% and partial responses in 51% vs. 2%. Disease control rate was 88% vs. 63%. OVERALL SURVIVAL: At the planned interim analysis, OS did not significantly differ between arms (median OS not reached with dabrafenib/trametinib vs. 25.9 months with placebo; HR=0.66; p=0.083); OS data remain immature, and interpretation is further confounded by near-universal crossover — 30 of 31 patients in the placebo group with confirmed progression crossed over to active therapy by the data cutoff. NNT for one additional objective response: [(1/0.57) − (1/0.04)] = approximately 2 patients needed to treat for one additional responder (calculated). SAFETY: Any-grade adverse events occurred in 98% of patients on the combination vs. 90% on placebo. The most common AEs with the combination were pyrexia (48%) and anemia (45%). Serious adverse events occurred in 43% (combination) vs. 25% (placebo). Grade ≥3 pneumonia was the most common severe AE (8% vs. 2%). Grade 5 (fatal) AEs in the combination arm included pneumonia (2%), bradycardia (1%), cerebrovascular accident (1%), septic shock (1%), and squamous cell carcinoma (1%); grade 5 events in the placebo arm included pericardial effusion and multiple organ dysfunction syndrome (1 patient each, 2%). Serous retinopathy occurred in 7% of combination patients vs. 0% of placebo patients. Treatment discontinuation due to AEs occurred in 8% (combination) vs. 6% (placebo). No new safety signals were identified.
Practice implications
This phase 3 trial establishes that dabrafenib plus trametinib produces statistically significant and clinically meaningful improvements in PFS and ORR in previously treated, BRAF V600E-positive, RAI-refractory differentiated thyroid cancer — a population with historically limited second-line options after VEGFR-targeted therapy. The absolute PFS gain of 9.1 months and ORR of 57% versus 4% are both statistically robust and clinically meaningful. However, the study did not establish an overall survival benefit at the interim analysis; OS data are immature, and the crossover design heavily limits any future OS interpretation. The safety profile, including pyrexia, anemia, serous retinopathy, and rare fatal events, is consistent with the established dabrafenib/trametinib class profile. Patients not adequately represented include those with ECOG PS >2, prior BRAF/MEK inhibitor exposure, non-BRAF V600E molecular subtypes, and anaplastic or poorly differentiated histology. Biomarker-driven patient selection (confirmed BRAF V600E mutation) is essential. IMPORTANT NOTE: Only the abstract was available for review; full data tables, forest plots, and pre-specified statistical analysis plans were not directly assessable, which limits assessment of subgroup heterogeneity and secondary endpoint robustness. __LIMITATIONS__ Small absolute sample size (n=153) limits power for subgroup analyses and rare event detection.,Overall survival data are immature, with the interim analysis not reaching statistical significance (p=0.083); near-universal crossover from placebo to active therapy after disease progression will likely preclude a definitive OS analysis.,Industry sponsorship (Novartis) introduces potential for reporting and design bias; authors have multiple Novartis-related disclosures.,Generalizability is uncertain: patients with ECOG PS >2, prior BRAF or MEK inhibitor exposure, or poorly differentiated/anaplastic histology were not enrolled.,PFS assessed by independent radiology review (RECIST v1.1) is appropriate but remains a surrogate endpoint; correlation with OS is not established in this disease setting.,Randomization stratification by number of prior VEGFR therapies and prior lenvatinib use is appropriate but does not adjust for all prognostic confounders.,The 2:1 allocation reduces placebo group power for safety comparisons.,Only the published abstract was available for this summary; full methods, statistical analysis plan, and supplementary data were not directly reviewed. __BOTTOM_LINE_CATEGORY__ practice_changing __BOTTOM_LINE__ In previously treated adults with BRAF V600E-positive, RAI-refractory differentiated thyroid cancer, dabrafenib plus trametinib significantly prolonged PFS (12.8 vs. 3.7 months; HR=0.38) and improved ORR (57% vs. 4%) compared with placebo, with no new safety signals — supporting its use as a second-line standard of care in this biomarker-selected population. An OS benefit was not demonstrated at the interim analysis, and data remain immature due to near-universal crossover. Clinicians should confirm BRAF V600E mutation status, counsel patients on class-specific toxicities (including pyrexia, anemia, and serous retinopathy), and await mature OS data before drawing conclusions about long-term survival impact.